Novartis (NVS) CEO says capital allocation priorities remain unchanged, will continue to do value creating Bolt on deals, via JPM conference

Novartis (NVS) CEO says capital allocation priorities remain unchanged, will continue to do value creating Bolt on deals, via JPM conference.

Novartis' CEO reaffirming its commitment to unchanged capital allocation priorities suggests a stable approach to growth, focusing on value-creating bolt-on acquisitions. This signals to the market that the company is looking to strategically enhance its portfolio, which could position it favorably against competitors in the pharmaceuticals sector and may attract investor confidence in its long-term growth strategy.